A June 2026 peer-reviewed publication in the International Journal of Dermatology highlights a wave of newly approved treatments for inflammatory skin diseases — conditions that frequently overlap with obesity and metabolic disorders, making this news directly relevant to people using GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound.
What Treatments Were Approved?
According to the publication, the FDA approved two notable therapies for psoriasis:
- Deucravacitinib, a tyrosine kinase 2 (TYK2) inhibitor
- Icotrokinra, described as the first oral interleukin-23 (IL-23) receptor antagonist peptide
For atopic dermatitis, the publication highlights new data on stapokibart, an interleukin-4 receptor alpha subunit (IL-4Rα) inhibitor introduced in China. The abstract also references a development in hidradenitis suppurativa involving glucagon-like peptide mechanisms, though the full details of that section were not available in the source material.
Why This Matters for GLP-1 Users
People living with obesity — a primary population for GLP-1 therapies — face elevated rates of inflammatory skin conditions. Psoriasis, atopic dermatitis, and hidradenitis suppurativa (HS) are all linked to chronic systemic inflammation, which also underlies metabolic disease. For patients already managing their weight or blood sugar with semaglutide or tirzepatide, the expansion of treatment options for these skin conditions represents a meaningful quality-of-life opportunity.
Notably, the truncated portion of the abstract specifically mentioned GLP-1 pathways in connection with hidradenitis suppurativa — suggesting researchers are actively exploring the intersection between GLP-1 biology and inflammatory skin disease, though no specific conclusions can be drawn from the available text.
Key takeaway: The FDA approved icotrokinra — the first oral IL-23 receptor antagonist peptide — for psoriasis in 2026, potentially offering a new pill-based option for patients who also use injectable GLP-1 therapies and prefer to reduce injection burden.
What Patients Should Know Right Now
If you are taking a GLP-1 medication and also managing a skin condition like psoriasis, eczema, or hidradenitis suppurativa, it is worth knowing:
- New oral and injectable biologics are now available or in advanced review
- Some of these therapies target inflammation pathways that may interact with the metabolic effects of GLP-1 drugs — a topic your dermatologist and prescribing physician should coordinate on
- The availability of an oral option (icotrokinra) for psoriasis may simplify treatment regimens for those already on weekly injections
What to Watch Next
Researchers appear to be investigating GLP-1 receptor activity in the context of hidradenitis suppurativa specifically. As more of the underlying study data becomes publicly available, clearer guidance may emerge on whether GLP-1 medications themselves offer any skin-related benefits — or whether dosing adjustments are needed when combining these drug classes. Follow updates from the International Journal of Dermatology and FDA drug approval announcements for further clarity.
Frequently Asked Questions
These developments signal an evolving treatment landscape for inflammatory skin diseases that commonly affect people also managing obesity or type 2 diabetes with GLP-1 therapies. As always, consult your prescriber or a board-certified dermatologist to determine which treatment options are appropriate for your individual health situation.
- PubMed peer-reviewed publication, Editor's Highlights-June 2026, International Journal of Dermatology, June 2026